Cancer Immunology – Webinars and Online Events

This event will feature discussions on novel immune checkpoint inhibitors, personalized cancer vaccines and CAR T-Cell therapies. We will also address the challenges of translating basic research into clinical practice and future directions.

Dr. Roddy O'Connor explores "hit & run" serial killing in CAR T cells, discussing how metabolic reprogramming influences their migration and cytolytic function, crucial for effective tumor targeting.

Dr. Jessica E. Thaxton discusses how metabolic stress in tumors affects immune cells, focusing on modulating T cells for lipid use and the role of Acetyl-CoA Carboxylase in limiting anti-tumor immunity.

Involved in immunotherapy research? Join our AMA Q&A with Professor Paul Moss to explore advances and applications in treating diseases. This hour-long virtual session lets you ask your questions live and dive deep into the field.

Key advances will be highlighted across the field of immuno-oncology. Hear a cross-section of experts discuss their research with a focus on basic research and a broad range of established and novel immunotherapeutics.

Join this webinar to discover how to integrate spatial biology and multiomics approaches to reveal the intricate interactions between cancer cells and their environment.

Explore cutting-edge cell and gene therapies at our online symposium on March 20–21. Experts will discuss cancer immunotherapy, gene therapy vectors, stem cells, and precision oncology research.

This webinar showcases the latest live-cell metabolic analysis technologies for the detection of cellular bioenergetic changes in human immune cells. It demonstrates real-world applications for the development and testing of life-saving therapeutics.

This webinar takes a closer look at immune cells in the tumor microenvironment (TME), helping us to gain a better understanding of how specific subtypes and their reprogramming may influence therapy efficiency.

Natural killer (NK) cells are a promising tool in the fight against cancer. Engineering them with chimeric antigen receptors (CARs) further bolsters their specific anti-tumor activity.